A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12.

被引：3
|
作者：
Ahlgren, Goran
Flodgren, Per
Tammela, Teuvo L. J.
Kellokumpu-Lehtinen, Pirkko
Borre, Michael
Angelsen, Anders
Iversen, Jon Reidar
Sverrisdottir, Asgerdur
Jonsson, Eirikur
Sengelov, Lisa
机构：
[1] Lund Univ, Skane Univ Hosp, Dept Urol, Malmo, Sweden
[2] Skane Univ Hosp, Lund, Sweden
[3] Tampere Univ Hosp, Dept Urol, Tampere, Finland
[4] Tampere Univ Hosp, Dept Oncol, Tampere, Finland
[5] Aarhus Univ Hosp, Dept Urol, Skejby Sygehus, Aarhus, Denmark
[6] Norwegian Univ Sci & Technol, Trondheim, Norway
[7] Dept Oncol, Oslo, Norway
[8] Dept Oncol, Reykjavik, Iceland
[9] Landspitali Univ Hosp, Reykjavik, Iceland
[10] KAS Herlev, Dept Oncol, Herlev, Denmark
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5001
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.
    Kellokumpu-Lehtinen, Pirkko-Liisa Irmeli
    Hjalm-Eriksson, Marie
    Astrom, Lennart
    Marttila, Timo
    Thellenberg-Karlsson, Camilla
    Nilsson, Sten
    Anders, Widmark
    Huttunen, Teppo
    Ginman, Claes
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy (RT) for intermediate and high-risk prostate cancer (PC): Quality-of-life results (QoL) in SPCG-13 trial
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Hjalm-Eriksson, Marie
    Thellenberg-Karlsson, Camilla
    Astrom, Lennart
    Franzen, Lars
    Fransson, Ann-Sofie
    Leskinen, Markku J.
    Huttunen, Teppo
    Ginman, Claes
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Adverse effect of docetaxel versus surveillance after radical prostatectomy for high risk prostate cancer: Post-hoc analysis of the prospective randomized, open-label phase III SPCG 12 trial.
    Ahlgren, Goran M.
    Borre, Michael
    Sengelov, Lisa
    Tammela, Teuvo L. J.
    Kellokumpu-Lehtinen, Pirkko
    Sverrisdottir, Asgerdur
    Iversen, Jon Reidar
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Adjuvant weekly docetaxel for high-risk prostate cancer patients after Radical Prostatectomy
    Kibel, AS
    Picus, J
    Cookson, MS
    Roth, B
    Jarrard, DF
    Wilding, G
    Klein, EA
    Dreicer, R
    Nelson, JB
    Chatta, G
    Benson, MC
    Petrylak, DP
    DiPaola, R
    Beer, TM
    Diamond, J
    Partin, AW
    Eisenberger, MA
    JOURNAL OF UROLOGY, 2005, 173 (04): : 222 - 222
  • [5] Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomy
    Kibel, AS
    Kattan, MW
    Picus, J
    Dreicer, R
    Klein, EA
    Wilding, G
    Jarrard, DF
    Roth, B
    Cookson, MS
    Pettylak, DP
    Chatta, G
    Nelson, JB
    Beer, TM
    Dipaola, R
    Partin, AI
    Rosenbaum, E
    Garrett, E
    Sugar, E
    Eisenberger, M
    JOURNAL OF UROLOGY, 2006, 175 (04): : 512 - 512
  • [6] Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
    Ahlgren, Goran M.
    Flodgren, Per
    Tammela, Teuvo L. J.
    Kellokumpu-Lehtinen, Pirkko
    Borre, Michael
    Angelsen, Anders
    Iversen, Jon Reidar
    Sverrisdottir, Asgerdur
    Jonsson, Eirikur
    Sengelov, Lisa
    EUROPEAN UROLOGY, 2018, 73 (06) : 870 - 876
  • [7] Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Hjalm-Eriksson, Marie
    Thellenberg-Karlsson, Camilla
    Astrom, Lennart
    Franzen, Lars
    Fransson, Ann-Sofie
    Leskinen, Markku J.
    Zeke, Mihalj
    Huttunen, Teppo
    Ginman, Claes
    EUROPEAN UROLOGY, 2019, 76 (06) : 823 - 830
  • [8] Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
    D'Andrea, David
    Shariat, Shahrokh F.
    Soria, Francesco
    EUROPEAN UROLOGY, 2018, 74 (05) : 680 - 681
  • [9] High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: A preplanned safety report of SPCG 13 trial
    Kellokumpu-Lehtinen, P.
    Hjelm-Eriksson, M.
    Thellenberg-Karlsson, C.
    Astrom, L.
    Franzen, L.
    Marttila, T.
    Taalikka, M.
    Ginman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [10] Veterans affairs cooperative studies program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer
    Montgomery, Bruce
    Lavori, Philip
    Garzotto, Mark
    Lee, Kelvin
    Brophy, Mary
    Thaneemit-Chen, Surai
    Kelly, William
    Basler, Joseph
    Ringer, Robert
    Yu, Wei
    Whittemore, Alice
    Lin, Daniel W.
    UROLOGY, 2008, 72 (03) : 474 - 480
12345